rs148987163
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PVS1PP5_Very_Strong
The NM_001386393.1(PANK2):c.1083-1G>T variant causes a splice acceptor, intron change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000317 in 1,609,604 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_001386393.1 splice_acceptor, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PANK2 | NM_001386393.1 | c.1083-1G>T | splice_acceptor_variant, intron_variant | ENST00000610179.7 | NP_001373322.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PANK2 | ENST00000610179.7 | c.1083-1G>T | splice_acceptor_variant, intron_variant | 1 | NM_001386393.1 | ENSP00000477429.2 |
Frequencies
GnomAD3 genomes AF: 0.00000669 AC: 1AN: 149420Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000160 AC: 4AN: 249920Hom.: 0 AF XY: 0.0000296 AC XY: 4AN XY: 135100
GnomAD4 exome AF: 0.0000342 AC: 50AN: 1460184Hom.: 0 Cov.: 32 AF XY: 0.0000289 AC XY: 21AN XY: 726338
GnomAD4 genome AF: 0.00000669 AC: 1AN: 149420Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 72930
ClinVar
Submissions by phenotype
Pigmentary pallidal degeneration Pathogenic:2Other:2
Pathogenic, no assertion criteria provided | literature only | OMIM | Nov 25, 2003 | - - |
not provided, no classification provided | literature only | GeneReviews | - | Pathogenic variant resulting in PKAN, originally seen in an individual diagnosed with HARP syndrome [Ching et al 2002] - |
not provided, no assertion criteria provided | literature only | OMIM | Mar 14, 2024 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 25, 2023 | This sequence change affects an acceptor splice site in intron 4 of the PANK2 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in PANK2 are known to be pathogenic (PMID: 11479594, 12510040). This variant is present in population databases (rs148987163, gnomAD 0.004%). Disruption of this splice site has been observed in individual(s) with neurodegeneration with brain iron accumulation (PMID: 14638969; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 4559). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. - |
Inborn genetic diseases Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 28, 2021 | The c.1413-1G>T intronic variant results from a G to T substitution one nucleotide before coding exon 5 of the PANK2 gene. Alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. This variant, designated as IVS4-1G>T, was reported in a cohort of individuals with pantothenate kinase-associated neurodegeneration; however, specific information was not provided (Hayflick, 2003). It was also identified in trans with a PANK2 missense variant in an individual with hypoprebetalipoproteinemia, acanthocytosis, retinitis pigmentosa, and pallidal degeneration (HARP) syndrome (Houlden, 2003). In silico splice site analysis predicts that this alteration will weaken the native splice acceptor site. Based on the available evidence, this alteration is classified as likely pathogenic. - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Jul 09, 2021 | PVS1, PS3_moderate, PM2 - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at